JPRN-UMIN000038715尚未招募2 期
Phase II neoadjuvant trial of nab-Paclitaxel+Pertuzumab+Trastuzumab followed by Anthracycline based regimen in patients with operable Her2 positive breast cancer - OMC-BC05 Study
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
已完成
2 期
Phase II study of neoadjuvant nab-paclitaxel and trastuzumab for ER negative and HER2 positive breast cancerER negative and HER2 positive breast cancerJPRN-UMIN000019616Osaka Medical College18
已完成
2 期
A study of neoadjuvant nab-paclitaxel followed by FEC for luminal B-like (HER2-negative) and triple-negative breast canceruminal B-like (HER2-negative) or triple-negative operable breast cancerJPRN-UMIN000017675Kyushu Breast Cancer Study Group (KBC-SG)94
已完成
不适用
A phase II study of nab-paclitaxel for pretreated non-small cell lung canceron-small cell lung cancerJPRN-UMIN000012972Kanagawa Cancer Center30
已完成
2 期
Phase II study of nab-paclitaxel for pretreated NSCLCon-small cell lung cancerJPRN-UMIN000014357Kitasato university hospital, division of respiratory medicine20
已完成
2 期
Phase II clinical study of nab-paclitaxel for patients with recurrent advanced non-small cell lung cancer.advanced non-small cell lung cancerJPRN-UMIN000016932The Japan-Multinational Trial Organization (JMTO)81